Healthcare Biz Roundup: Keryx Jumps Without CAUSE, Teva Not A MONOPOLIST

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Abbott Labs’ (NYSE:ABT) Healon EndoCoat OVD gel gets FDA approval, and shares climb modestly. The product is used in cataract procedures and in implanting intraocular lenses its market is quite large, with almost 3 million persons undergoing cataract surgery in the United States yearly.

Don’t Miss: Warren Buffett Picks a WINNER with Walmart.

It’s one of those weird days when shares of some company skyrocket for no apparent cause. Keryx Biopharmaceuticals (NASDAQ:KERX) jumps nearly ten percent Tuesday, without an obvious catalyst. Chatter at Yahoo Finance speculates that the jump could be due to insider buying, and Five Star Equities speculates that the firm could be a possible acquisition target, as Big Pharma needs to replace expiring patents.

Teva’s (NASDAQ:TEVA) proposed purchase of Cephalon gets cleared by the FTC, as it okays an amended final order to that effect, settling charges that the acquisition would have stifled competition. However, Teva must now divest the rights and assets related to a generic cancer pain med and a generic muscle relaxant to Par Pharmaceuticals (NYSE:PRX), and also allow PRX to sell a generic version of Cephalon’s narcolepsy medication Provigil in 2012.

Don’t Miss: Is a New Kid on the Block Eyeing Apple and Google?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business